NCT07187778 2026-01-05Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)M.D. Anderson Cancer CenterPhase 2 Recruiting10 enrolled
NCT06677190 2025-11-05Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic OriginDana-Farber Cancer InstitutePhase 2 Recruiting32 enrolled